Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 100,000 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 100,000 shares of Immunome stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00. Following the completion of the sale, the director directly owned 208,504 shares in the company, valued at $4,710,105.36. This trade represents a 32.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Price Performance

Shares of IMNM opened at $23.61 on Friday. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The stock’s fifty day moving average price is $20.96 and its two-hundred day moving average price is $21.78. The firm has a market cap of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. Sell-side analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IMNM. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Friday, June 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Leerink Partners lowered their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Barclays initiated coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Institutional Investors Weigh In On Immunome

Several large investors have recently added to or reduced their stakes in IMNM. Creative Planning raised its position in Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Immunome by 1.8% in the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Assetmark Inc. increased its position in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares during the last quarter. Finally, Virtus Investment Advisers LLC raised its holdings in shares of Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.